United States v. William Schureck

CourtCourt of Appeals for the Sixth Circuit
DecidedMarch 1, 2018
Docket16-4267
StatusUnpublished

This text of United States v. William Schureck (United States v. William Schureck) is published on Counsel Stack Legal Research, covering Court of Appeals for the Sixth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States v. William Schureck, (6th Cir. 2018).

Opinion

NOT RECOMMENDED FOR FULL-TEXT PUBLICATION File Name: 18a0103n.06

Case Nos. 16-4261, 16-4267, 16-4271, 16-4287 FILED Mar 01, 2018 UNITED STATES COURT OF APPEALS DEBORAH S. HUNT, Clerk FOR THE SIXTH CIRCUIT

UNITED STATES OF AMERICA, ) ON APPEAL FROM THE ) UNITED STATES DISTRICT Plaintiff-Appellee, ) COURT FOR THE ) NORTHERN DISTRICT OF v. ) OHIO ) DARYL DANE DONOHUE (16-4261); ) WILLIAM SCHURECK (16-4267); ) KENNETH JACKSON (16-4271); DENNIS ) DECIANCIO (16-4287), ) ) Defendants-Appellants. ) ________________________________________

OPINION OF THE COURT

BEFORE: DAUGHTREY, McKEAGUE, and BUSH, Circuit Judges.

McKEAGUE, Circuit Judge. These four consolidated appeals stem from judgments on

jury verdicts finding all four defendants guilty of numerous charges relating to an investment

fraud scheme. The scheme revolved around development of a hypodermic syringe destruction

device called the “Sharps Terminator.” The jury found that defendants had made material

misrepresentations and omitted material facts in soliciting funding for development of the

product. Defendants were sentenced to various terms of imprisonment and ordered to pay

restitution to the victims in the total amount of nearly $10 million. On appeal, defendants assert

-1- Case Nos. 16-4261/4267/4271/4287, United States v. Donohue, et al.

various claims of error that raise several common themes. None has been shown to merit relief.

We therefore affirm all four judgments.

I. BACKGROUND

In August 1992, defendant Kenneth Jackson was convicted in Ohio state court of multiple

counts of unlicensed sales of securities and sales of unregistered securities, passing bad checks,

perjury, theft and aggravated theft. The convictions stemmed from Jackson’s operation of what

the government has characterized as a $13 million Ponzi scheme involving sales of securities in

“Vision Television Network.” As a consequence, Jackson was incarcerated from 1992 to 1999.1

He was also prohibited, by injunction of the Securities and Exchange Commission (“SEC”),

from holding any corporate officer or director position in a publicly traded company. Jackson

was also subject to a disgorgement order requiring him to pay $1.8 million to the SEC.

Despite these setbacks, in 2002, Jackson had become director of research and

development for Event Future (a/k/a E-Med), a company he and co-defendant Daryl Dane

Donohue established to design and manufacture a hypodermic needle destruction device called

“Needlezap.” The Needlezap disposes of used needles by crushing them. It is a Class III

medical device requiring Food & Drug Administration (“FDA”) approval before marketing.

Donohue was employed by E-Med to address the FDA’s regulatory compliance requirements.

The Needlezap was granted FDA approval in 2003 and was patented in 2006.

In 2007, Jackson left E-Med and he and co-defendant William Schureck created Medical

Safety Solutions (“MSS”) to develop and market an improved version of the Needlezap called

the “Sharps Terminator.” The Sharps Terminator was designed to dispose of used needles by

1 During his imprisonment, Jackson became acquainted with at least two individuals who would later become associated with him as employees in the design and manufacturing operations at the center of the instant prosecution. -2- Case Nos. 16-4261/4267/4271/4287, United States v. Donohue, et al.

incinerating them. Again, FDA premarket approval was required. Donohue was hired by MSS

as a regulatory compliance consultant, but Jackson, director of research and development, was

responsible for obtaining FDA approval of the Sharps Terminator. Schureck was Chief

Executive Officer of MSS.

To raise funds for development of the Sharps Terminator by selling securities, MSS

prepared two prospectuses, “Prospectus A” (2007) and “Prospectus B” (2009). Prospectus A

disclosed an Assets Purchase Agreement under which MSS agreed to pay Jackson and Schur

Partnership (a venture established by Schureck) $3 million for transfer of ownership of the

Sharps Terminator, along with its patent and intellectual property rights. What the prospectuses

did not include, relevantly, was any mention of MSS co-founder Jackson’s prior convictions for

theft and securities fraud offenses. Nor did the prospectuses disclose that the conduct for which

Jackson was convicted also precipitated action by the SEC that resulted in a $1.8 million

judgment against him, as well as an injunction prohibiting him from holding any officer or

director position in a publicly traded company.

In the summer of 2007, MSS began displaying its plans for the Sharps Terminator and

soliciting investments at medical trade shows. MSS raised $5 million from investors in response

to Prospectus A. Among the first such investors, co-defendant Dennis DeCiancio invested

$275,000 and became a promoter of the Sharps Terminator at trade shows. Of the $5 million

received, $3 million was to be used to pay for the intellectual property rights in the Sharps

Terminator and to repay prior investors in the Needlezap, and $2 million was to be used for

further research and development of the Sharps Terminator.

In July 2007, MSS also purportedly commenced efforts to obtain FDA premarket

approval and told inquiring investors for years that progress was slow, but approval was

-3- Case Nos. 16-4261/4267/4271/4287, United States v. Donohue, et al.

imminent. In fact, Jackson testified, it was not until October 2012 that he first filed the

application for premarket approval. The FDA responded to the application a month later with

the first of several deficiency letters, which MSS was attempting to address when, in March

2013, its efforts were undercut by execution of a search warrant and seizure of MSS files and

records. In the meantime, the FBI had begun investigating MSS’s operations.2

The investigation ripened into an 80-page, 31-count indictment in the Northern District of

Ohio in July 2015, charging all four of the above-named defendants—Jackson, Donohue,

Schureck and DeCiancio—with numerous offenses allegedly committed between November

2007 and May 2013, including conspiracy, mail fraud, wire fraud, securities fraud, and money

laundering. The charges were premised on allegations that defendants, in soliciting investments

for development and marketing of the Sharps Terminator device: falsely represented the status

of FDA premarket approval proceedings, the market-readiness of the Sharps Terminator, and the

use to which invested funds would be applied; and failed to disclose material information to

prospective investors about Jackson’s prior convictions.

A joint jury trial was conducted in April and May 2016 and culminated in verdicts on

May 6, 2016, finding all four defendants guilty of almost all charged offenses. All four

defendants were sentenced on October 25, 2016, to various prison terms: Jackson to

188 months, Schureck to 108 months, DeCiancio to 70 months, and Donohue to 46 months. The

judgments of sentence were entered on November 1, 2016, and each defendant timely filed

notice of appeal. The judgments were followed by a restitution order on January 5, 2017,

2 In May 2013, MSS entered into a license agreement whereby its rights to the Sharps Terminator were sold to Sharps Terminator, LLC, in exchange for payment of one-third of net profits from sales of the Sharps Terminator.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

TSC Industries, Inc. v. Northway, Inc.
426 U.S. 438 (Supreme Court, 1976)
Jackson v. Virginia
443 U.S. 307 (Supreme Court, 1979)
Basic Inc. v. Levinson
485 U.S. 224 (Supreme Court, 1988)
United States v. Dominguez Benitez
542 U.S. 74 (Supreme Court, 2004)
Eberhart v. United States
546 U.S. 12 (Supreme Court, 2005)
Gall v. United States
552 U.S. 38 (Supreme Court, 2007)
Puckett v. United States
556 U.S. 129 (Supreme Court, 2009)
United States v. Faulkenberry
614 F.3d 573 (Sixth Circuit, 2010)
United States v. Blanchard
618 F.3d 562 (Sixth Circuit, 2010)
United States v. James Streets
401 F. App'x 81 (Sixth Circuit, 2010)
United States v. Warshak
631 F.3d 266 (Sixth Circuit, 2010)
United States v. McCarty
628 F.3d 284 (Sixth Circuit, 2010)
United States v. Nicholas Bachynsky
415 F. App'x 167 (Eleventh Circuit, 2011)
United States v. Randolph Speer
419 F. App'x 562 (Sixth Circuit, 2011)
United States v. Boyd
640 F.3d 657 (Sixth Circuit, 2011)
United States v. Fisher
648 F.3d 442 (Sixth Circuit, 2011)
United States v. Wesley E. Hixon
987 F.2d 1261 (Sixth Circuit, 1993)
United States v. Demmler
655 F.3d 451 (Sixth Circuit, 2011)
United States v. Clay
667 F.3d 689 (Sixth Circuit, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
United States v. William Schureck, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-v-william-schureck-ca6-2018.